The utilization of nutrients from the environment by normal cells is controlled by fine-tuned mechanisms regulated by growth factor signals. Cancer cells overcome this growth factor dependence by acquiring genetic mutations that rewire signaling pathways that affect the uptake of nutrients, and reprogram metabolism to fuel the biosynthetic processes required to support their altered cell growth, survival and proliferation [1]. This rewiring for growth may make tumors more vulnerable to nutrient deprivation, however. For instance, growing evidence demonstrates that cancer-promoting mutations result in addiction in vitro. In research published in Cell and Bioscience, Jiang and colleagues show that pharmacological restriction of glucose metabolism decreases tumor progression in a TSC xenograft model.

The elevated metabolic requirements of cancer cells reflect their rapid growth and proliferation and are met through mutations in oncogenes and tumor suppressor genes that reprogram cellular processes. For example, in tuberous sclerosis complex (TSC)-related tumors, the loss of TSC1/2 function causes constitutive mTORC1 activity, which stimulates glycolysis, resulting in glucose addiction in vitro. In research published in Cell and Bioscience, Jiang and colleagues show that pharmacological restriction of glucose metabolism decreases tumor progression in a TSC xenograft model.

The glucose appetite of tumors and its regulation by mTORC1

Research efforts have sought to characterize tumor cell metabolism since Otto Warburg’s observations in the 1920s of the tendency of cancer cells to metabolize glucose into lactate despite sufficient oxygen levels (known as the Warburg effect or ‘aerobic glycolysis’). By contrast, most differentiated cells primarily metabolize glucose to carbon dioxide by oxidation of pyruvate in the mitochondrial tricarboxylic acid (TCA) cycle, a process known as oxidative phosphorylation that requires far less glucose to generate the same amount of energy. The heightened appetite of tumor cells for glucose has been put to diagnostic use, as high rates of glucose utilization can be detected using [18F]-fluorodeoxyglucose positron emission tomography (FDG-PET), providing images in which tumors often appear as PET-positive as the most metabolically active tissues. Understanding why and how the Warburg effect occurs has posed a puzzle, however, as it is not immediately obvious why aerobic glycolysis should be favored in tumors when it is an inefficient way to generate energy. It is thought that the Warburg effect supports tumor growth by diverting glucose to macromolecular precursors, such as acetyl-CoA for fatty acids, glycolytic intermediates for nonessential amino acids, and ribose for nucleotides [3].

In normal cells the switch from a non-proliferating state, in which oxidative phosphorylation meets the cell’s energy needs, to proliferation, in which glycolysis dominates, is triggered by growth factors acting through the mammalian Target of Rapamycin Complex 1 (mTORC1) signaling pathway (Figure 1). This pathway allows cells to integrate information about environmental conditions and to balance catabolic and anabolic processes accordingly. Growth factor-activated kinases phosphorylate and inhibit the tumor sclerosis complex TSC1-TSC2, allowing the small G protein Rheb to activate mTORC1.
addition, mTORC1 is sensitive to intracellular energy levels through the AMP-activated protein kinase (AMPK). In response to energy deprivation, AMPK phosphorylates TSC2, and the mTORC1 component raptor, resulting in mTORC1 inhibition and a reduction of energy consumption [4] (Figure 1). The most recognized function for mTORC1 is the promotion of protein synthesis through the phosphorylation of at least two direct downstream targets, the ribosomal S6 kinases (S6K1 and S6K2), and the translation repressors 4E-BP1 and 4E-BP2 [4] (Figure 1). However, studies using the mTORC1-specific inhibitor rapamycin have revealed a broader role of mTORC1 in regulating the metabolic processes that support cell growth and proliferation (Figure 2).

In addition to driving protein synthesis, activation of mTORC1 promotes glycolysis by up-regulating Hypoxia-inducible factor (HIF1α) and c-Myc, which in turn promote the expression of proteins involved in nearly every step of the glycolytic pathway. mTORC1 activation
also contributes to the Warburg effect by diverting pyruvate away from oxidation in mitochondria. This is achieved by increased expression of lactate dehydrogenase, which converts pyruvate to lactate, and pyruvate dehydrogenase kinase, which inhibits the conversion of pyruvate to acetyl-CoA. Furthermore, mTORC1 stimulates de novo lipogenesis by promoting the expression of genes regulated by the sterol regulatory element-binding protein (SREBP1), thereby promoting the synthesis of the fatty acids needed for new cell membranes. Interestingly, mTORC1 activation is also sufficient to stimulate the expression of genes encoding the enzymes involved in the pentose phosphate pathway (PPP), including glucose 6-phosphate dehydrogenase (G6PD) in an SREBP1-dependent manner. Activation of the PPP provides cells with sources of NADPH to drive anabolic metabolism, as well as the generation of ribose 5-phosphate for de novo nucleotide biosynthesis [5] (Figure 2). It remains to be determined whether the mTORC1 pathway influences the metabolism of glutamine (glutaminolysis), an abundant nutrient essential for cancer cell bioenergetics and proliferation. It is known that c-Myc can stimulate glutamine catabolism [6], however, suggesting that mTORC1-dependent regulation of c-Myc promotes glutaminolysis as well as glycolysis.

In sum, the various metabolic outcomes of activating the mTORC1 pathway render cells dependent on glucose and perhaps glutamine to support their biosynthetic needs for rapid growth and proliferation. In normal cells, mTORC1 activation is regulated in accordance with the
needs of the organism, but in cancer cells, mutations in various oncogenes or tumor suppressors can lead to its aberrant activation (Figure 1). In TSC-related tumors the loss of the TSC1/2 complex leads to mTORC1 activation irrespective of growth factor or energy levels, and also to reduced insulin-stimulated glucose uptake [7], resulting in an impaired ability to balance metabolic demand with supply. Whether the consequent hypersensitivity of TSC-related tumors to glucose deprivation that is observed in vitro [8] can be exploited therapeutically in vivo is addressed by the study of Jiang et al. [2].

The glucose addiction of TSC-mutant tumors as a therapeutic target
TSC is an autosomal dominant genetic disease with an incidence of 1 in 6,000 at birth, and nearly 1,000,000 people worldwide are known to have TSC. TSC is due to genetic inheritance or spontaneous inactivating mutations in either TSC1 or TSC2 genes, and is characterized by the formation of non-invasive benign tumors in many organs. Rapamycin and its analogues, because of their inhibitory effect on the mTORC1 pathway, have been examined as potential therapeutic agents in the treatment of TSC; however, early studies have demonstrated that while these drugs can reduce tumor size, the tumors return after treatment stops [9]. Therefore, identifying new therapeutic options that can specifically eliminate TSC tumors remains an important goal. Targeting cellular metabolism has received particular attention during the past few years as an alternative strategy for cancer therapy, and could prove an important approach for treating TSC based on the rationale that TSC1/2/-/- cells require glucose for survival [8].

The research of Jiang et al. [2] sought to examine the effects of the glycolytic inhibitor 2-deoxy-β-glucose (2-DG) and a diet free of carbohydrates on the growth of LEF2 cells from a Tsc2-null rat tumor implanted in mice. The expression of these cells to 2-DG resulted in decreased cell viability at low glucose concentration. 2-DG is an analog of glucose in which the 2-hydroxyl group has been replaced by hydrogen, thus preventing it from undergoing glycolysis. This leads to reduced cellular ATP levels and subsequently cell growth. Jiang et al. show that 2-DG treatment suppresses tumor growth by reducing cell proliferation in this model, although they did not show whether this is accompanied by apoptosis as occurs in vitro [2]. These observations suggest that 2-DG is a promising antitumor therapy and, in fact, this compound is being used to treat osteosarcomas and lung cancers in phase II clinical trials. However, pre-trial studies show that 2-DG, as is the case with other glycolysis inhibitors, does not have a significant effect on tumor growth when used on its own as a monotherapy, although it can sensitize tumors to chemotherapeutic agents such as paclitaxel [10]. The differences between previous studies and the results shown by Jiang et al. raise the question of whether 2-DG effects are dependent on the type of tumor, and if this could be specifically related to the hypersensitivity of TSC2/-/- tumors to glucose deprivation.

Jiang et al. also tested the effects of a diet free of carbohydrates in their model, anticipating that this would also deprive the TSC2/-/- tumors of glucose, and add to the effects of 2-DG. However their diet (which was carbohydrate-free but not calorie-restricted) produced some unexpected results. In humans a carbohydrate-free diet leads to reduced blood glucose and an increased production of ketone bodies as nutrients other than glucose are used to produce energy [11], but in the mice fed with a carb-free diet in the study of Jiang et al. levels of β-hydroxybutyrate (HOB), a ketoacid, were not affected and blood glucose remained high [2]. Strikingly, and in contrast to the results of 2-DG treatment, this diet resulted in larger tumors with increased necrosis and zones of liquefaction. These large tumors did not appear to be fueled by glucose, however, as the diet was effective in decreasing the uptake of [18F]-fluorodeoxyglucose (FDG), suggesting that nutrient sources other than glucose are fuelling anabolism and survival under these conditions [2].

The carb-free diet provides abundant fatty acids that are broken down by beta-oxidation into acetyl-CoA, a major substrate for energy and biomass production through the TCA cycle. Interestingly, a recent report demonstrates that high-grade primary tumors contain elevated levels of fatty acids that contribute to the proliferation of aggressive cancer cells by increasing the levels of signaling lipids such as phosphatidic acid, lysophosphatidic acid and prostaglandin E2. [12]. Consistent with this, Jiang et al. [2] show that treatment of LEF2 cells with oleic acid results in increased proliferation and survival. In contrast, treatment with the saturated palmitic acid induces apoptosis in LEF2 cells, an observation that might be relevant to the increased areas of necrosis observed in the tumors of carb-free fed mice [2].

While the carb-free diet failed to inhibit TSC tumor progression, the 2-DG effects on tumor growth are promising and encouraging for future clinical trials in TSC patients. However, toxicity due to off-target effects has been attributed to this compound in clinical trials, and three of ten mice in this study were sacrificed early on account of weight loss during 2-DG treatment [2], suggesting that there are inherent difficulties in an approach that attempts to starve a tumor but not the organism that hosts it. One way of overcoming toxicity problems while improving efficacy is to use combination therapies, and for TSC-related tumors there are good reasons to consider these in future studies. TSC tumors
display low FDG uptake on PET imaging despite increased glycolytic flux [13], suggesting that a glucose-independent nutrient source is fueling the cells. Moreover, recent work has demonstrated that glutamine is required to maintain the cellular bioenergetics of TSC-/- cells [14]. Therefore combination therapies targeting both glutamine and glucose addiction might be effective.

Cancer therapy is increasingly shifting toward individualized therapeutic approaches based on the genetic abnormalities exhibited by transformed cells. Jiang et al. [2] demonstrate that targeting glucose addiction is an effective approach for decreasing the growth of tumors driven by TSC mutations. Thus glucose addiction may prove to be the ‘Achilles’ heel’ for the treatment of TSC. Whether these findings will translate to other tumor types, in which the constitutive activation of mTORC1 is a result of different genetic abnormalities, and whether the toxic side effects of 2-DG can be overcome, however, remains to be seen.

Acknowledgments
We would like to thank the members of the Blenis lab for helpful comments on the manuscript, especially Sarah Mahoney, Gwen Buel and Xiaoxiao Gu. AC is supported by a fellowship from the LAM Foundation.

Published: 21 October 2011

References
1. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB: The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 2008, 7:11-20.
2. Jiang X, Kenerson H, Yeung R: Glucose deprivation in tuberous sclerosis complex-related tumors. Cell and Bioscience 2011, 1:34
3. Vander Heiden MG, Cantley LC, Thompson CB: Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009, 324:1029-1033.
4. Mahoney SJ, Dempsey JM, Blenis J: Cell signaling in protein synthesis ribosome biogenesis and translation initiation and elongation. Prog Mol Biol Transl Sci 2009, 90:53-107.
5. Düvel K, Yecies JL, Menon S, Raman P, Lipovsky AI, Souza AL, Triantafellow E, Ma Q, Gonski R, Cleaver S, Vander Heiden MG, MacKeigan JP, Finan PM, Clish CB, Murphy LO, Manning BD: Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol Cell 2010, 39:171-183.
6. Gao P, Tchernyshyov I, Chang TC, Lee YY, Kita K, Ochi T, Zeller KI, De Marzo AM, Van Eyk JE, Mendell JT, Dang CV: c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 2009, 458:762-765.
7. Jiang X, Kenerson H, Aicher L, Miyaoka R, Eary J, Bissler J, Yeung RS: The tuberous sclerosis complex regulates trafficking of glucose transporters and glucose uptake. Am J Pathol 2008, 172:1748-56.
8. Inoki K, Zhu T, Guan KL: TSC2 mediates cellular energy response to control cell growth and survival. Cell 2003, 115:577-590.
9. Bissler JJ, McCormack FX, Young LR, Elwing JM, Chuck G, Leonard JM, Schmittorst VJ, Laor T, Brody AS, Bean J, Salsbury S, Franz DN: Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 2008, 358:140-151.
10. Mascheq G, Savaraj N, Priebe W, Braunischweiger P, Hamilton K, Tidmarsh GF, De Young LR, Lampidis TJ: 2-deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo. Cancer Res 2004, 64:31-34.
11. Bologn CI, Westman EC, Yancy WS Jr: Carbohydrate-restricted diets for obesity and related diseases: an update. Curr Atheroscler Rep 2009, 11:462-469.
12. Nomura DK, Long JZ, Niessen S, Hoover HS, Ng SW, Cravatt BF: Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. Cell 2010, 140:49-61.
13. Young LR, Franz DN, Nagarkatte P, Fletcher CD, Wikenheiser-Brockamp KA, Galisky MD, Corbridge TC, Lam AP, Gelfand M, McCormack FX: Utility of [18F]2-fluoro-2-deoxyglucose-PET in sporadic and tuberous sclerosis-associated lymphangioleiomyomatosis. Chest 2009, 136:926-933.
14. Choo AV, Kim SG, Vander Heiden MG, Mahoney SJ, Yu H, Yoon SO, Cantley LC, Blenis J: Glucose addiction of TSC-null cells is caused by failed mTORC1-dependent balance of metabolic demand with supply. Mol Cell 2010, 38:487-499.

doi:10.1186/1741-7007-9-69

Cite this article as: Csibi A, Blenis J: Appetite for destruction: the inhibition of glycolysis as a therapy for tuberous sclerosis complex-related tumors. BMC Biology 2011, 9:69.